AR076479A1 - PHARMACEUTICAL COMPOSITIONS FOR MAINTENANCE THERAPIES CONTAINING AS AN ACTIVE INGREDIENT AN ANTIBODY RECOGNIZING THE CLASS I HUMAN LEUCOCITARY ANTIGEN (HLA) - Google Patents

PHARMACEUTICAL COMPOSITIONS FOR MAINTENANCE THERAPIES CONTAINING AS AN ACTIVE INGREDIENT AN ANTIBODY RECOGNIZING THE CLASS I HUMAN LEUCOCITARY ANTIGEN (HLA)

Info

Publication number
AR076479A1
AR076479A1 ARP100101423A ARP100101423A AR076479A1 AR 076479 A1 AR076479 A1 AR 076479A1 AR P100101423 A ARP100101423 A AR P100101423A AR P100101423 A ARP100101423 A AR P100101423A AR 076479 A1 AR076479 A1 AR 076479A1
Authority
AR
Argentina
Prior art keywords
class
hla
active ingredient
pharmaceutical compositions
antigen
Prior art date
Application number
ARP100101423A
Other languages
Spanish (es)
Inventor
Toshio Matsumoto
Masahiro Abe
Shuji Ozaki
Kohji Itoh
Daisuke Tsuji
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR076479A1 publication Critical patent/AR076479A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones farmacéuticas para terapias de mantenimiento, que incluye como ingrediente activo un anticuerpo que reconoce el antígeno leucocitario humano (HLA) de Clase I. Métodos para mantener el estado alcanzado después de un tratamiento de cáncer (estado de post-terapia), inclusive el paso de administrarle a un sujeto un anticuerpo que reconoce el HLA de Clase I. Reivindicacion 6: Uso de un anticuerpo que reconoce HLA de Clase I caracterizado porque es para la elaboracion de una composicion farmacéutica para una terapia de mantenimiento. Reivindicacion 11: Un anticuerpo que reconoce HLA de Clase I caracterizado porque se usa en el mantenimiento de un estado alcanzado después del tratamiento de una enfermedad (usado en la terapia de mantenimiento de la enfermedad).Pharmaceutical compositions for maintenance therapies, which includes as an active ingredient an antibody that recognizes the human leukocyte antigen (HLA) of Class I. Methods to maintain the state reached after a cancer treatment (post-therapy state), including the passage of administering to an individual an antibody that recognizes the HLA of Class I. Claim 6: Use of an antibody that recognizes HLA of Class I characterized in that it is for the elaboration of a pharmaceutical composition for a maintenance therapy. Claim 11: An antibody that recognizes HLA Class I characterized in that it is used in the maintenance of a condition reached after treatment of a disease (used in disease maintenance therapy).

ARP100101423A 2009-04-28 2010-04-28 PHARMACEUTICAL COMPOSITIONS FOR MAINTENANCE THERAPIES CONTAINING AS AN ACTIVE INGREDIENT AN ANTIBODY RECOGNIZING THE CLASS I HUMAN LEUCOCITARY ANTIGEN (HLA) AR076479A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009109563 2009-04-28

Publications (1)

Publication Number Publication Date
AR076479A1 true AR076479A1 (en) 2011-06-15

Family

ID=43032218

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101423A AR076479A1 (en) 2009-04-28 2010-04-28 PHARMACEUTICAL COMPOSITIONS FOR MAINTENANCE THERAPIES CONTAINING AS AN ACTIVE INGREDIENT AN ANTIBODY RECOGNIZING THE CLASS I HUMAN LEUCOCITARY ANTIGEN (HLA)

Country Status (4)

Country Link
JP (1) JPWO2010126074A1 (en)
AR (1) AR076479A1 (en)
TW (1) TW201105347A (en)
WO (1) WO2010126074A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2517555A4 (en) 2009-12-25 2014-09-24 Chugai Pharmaceutical Co Ltd Method for searching and screening for target of anti-cancer agent using non-human animal model having nog established cancer cell line transplanted therein
SG189302A1 (en) 2010-10-06 2013-05-31 Pharmalogicals Res Pte Ltd Cancer stem cell population and method for production thereof
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
JP6291254B2 (en) * 2011-10-28 2018-03-14 中外製薬株式会社 Cancer stem cell specific molecule

Also Published As

Publication number Publication date
TW201105347A (en) 2011-02-16
JPWO2010126074A1 (en) 2012-11-01
WO2010126074A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
AR092177A1 (en) METHODS TO TREAT OR PREVENT ASTHMA BY MANAGING AN IL-4R ANTAGONIST
CO7200273A2 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
SV2011003939A (en) VEGF-R2 PIRIDYLOXI-INDOLES INHIBITORS AND USE OF THE SAME FOR THE TREATMENT OF DISEASES
AR091876A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
ECSP12011834A (en) Pharmaceutical composition, pharmaceutical dosage form, procedure for its preparation, methods for its treatment and its uses.
CR11455A (en) NEW CYCL HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES
GT201000182A (en) DOSAGE REGIME ASSOCIATED WITH INJECTABLE PALIPERIDONE ESTERS OF PROLONGED ACTION
ECSP14013217A (en) 4-IMIDAZOPIRIDAZIN-1-IL-BENZAMIDAS AND 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDAS AS BTK INHIBITORS.
GT200600297A (en) NEW ANTI-MADCAM ANTIBODIES
GT201400069A (en) PHARMACEUTICAL COMPOSITIONS
BR112015022465A2 (en) Non-toxic treatment method for drug withdrawal syndrome
CL2017003066A1 (en) Compositions of amorphous calcium carbonate for administration by inhalation, sublingual or buccal
CR20140144A (en) DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
EA201400002A1 (en) METHODS TO TREAT DISEASES OF THE RETAIL
MX2017004772A (en) Compositions and methods for physiological delivery using cannabidiol.
CL2015000039A1 (en) Estra-1,3,5 (10), 16-tetraeno-3-substituted derivatives, pharmaceutical preparations that comprise them and their use in the preparation of medicaments for treating endometriosis.
CL2013003298A1 (en) Use of methotrexate because it is used to prepare a medicine, useful in the treatment of diseases that need treatment with a therapeutic product that produces autoimmunity, administered in a single cycle.
BR112015007647A2 (en) ketamine derivatives
BR112014011981B8 (en) ORAL SOLID PHARMACEUTICAL FORMULATIONS, THEIR PREPARATION PROCESSES AND USES
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
AR076479A1 (en) PHARMACEUTICAL COMPOSITIONS FOR MAINTENANCE THERAPIES CONTAINING AS AN ACTIVE INGREDIENT AN ANTIBODY RECOGNIZING THE CLASS I HUMAN LEUCOCITARY ANTIGEN (HLA)
AR079000A1 (en) ANTI-BANK THERAPY AIMED AT CANCEROSA MOTHER RESISTANT DRUG CELLS
AR098832A1 (en) USE OF LAQUINIMOD TO DELAY THE PROGRESSION OF HUNTINGTON'S DISEASE
UY33529A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES?
CO7111317A2 (en) Method for the treatment of gynecological diseases

Legal Events

Date Code Title Description
FB Suspension of granting procedure